Carisma Therapeutics Inc (CARM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CARM Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Carisma Therapeutics Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2025)
(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Assets
Cash & cash equivalent2.78
Cash & Short-term Investments2.00
Disposal Group, Including Discontinued Operation, Assets, Current AS0.00
Prepaid Expense And Other Assets Current3.09
Total Current Assets5.87
Other Assets, Noncurrent0.68
Total Assets6.55
Liabilities
Accounts Payable, Current AC5.57
Accrued Liabilities, Current AC1.09
Other Liabilities, Current0.15
Deferred Revenue, Current DE0.00
Total Current Liabilities6.81
Total Long-term Debt0.00
Deferred Revenue, Noncurrent DE0.00
Other liabilities, Noncurrent0.61
Total Liabilities7.42
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock278.99
Retained Earnings / Accumulated Deficit-279.90
Other Equity0.00
Common Stockholder's Equity-0.87
Total Stockholder's Equity-0.87
Liabilities & Stockholder's Equity6.55
4 historic quarters locked

Sign in to unlock the full Carisma Therapeutics Inc balance sheet history.

About Carisma Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-25-110444

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.